Psoriatic arthritis: interaction between cardiometabolic diseases and inflammatory burden of the disease

Autor: María Colazo Burlato, Marina Pino Martinez, José Andrés Lorenzo Martín, Estefanía Pardo Campo, Manuel Rubén Queiro Silva
Rok vydání: 2020
Předmět:
Zdroj: Reumatologia clinica. 18(7)
ISSN: 2173-5743
Popis: Psoriatic arthritis is accompained by several cardiometabolic comorbidities. Obesity causes a low-grade systemic inflammation and is a negative predictor of treatment response. We wanted to evaluate if there are interactions between metabolic status, inflammatory parameters and disease activity; and whether metabolic or cardiovascular diseases have any association with the reduction of the inflammatory burden by treating the psoriatic arthritis.We have carried out a cross-sectional descriptive study of 160 patients with psoriatic arthritis. Sociodemographic, clinical and analytical variables were collected, as well as the presence of dactylitis and enthesitis; and HAQ, DAPSA and Minimal Disease Activity criteria. Chi-square test and the H of Kruskall Wallis were used to carry out comparisons, considering P.05 as statistically significant. To establish correlations, Pearson correlation coefficient was used.BMI and waist circumference correlate with CRP and ESR (significance:.05) although the correlation strenght is low (Pearson.4), but there is no such relationship with DAPSA or meeting MDA criteria. Using biologic therapies is associated with a lower prevalence of cardiovascular events (P = 0.047; OR: 0.12, 95% CI: 0.01-0.9) and enthesitis (P = .008; OR: 0.3, CI 95%: 0.16-0.56); and normal levels of CRP (P = .029; OR: 0.25, 95% CI: 0.07-0.87) and ESR (P = 0.024; OR: 0.36, 95% CI: 0.16-0.82) when comparing to conventional therapies.Anti-TNFα treatment could reduce cardiovascular risk in patients with psoriatic arthritis. There may be higher levels of CRP and ESR in obese individuals without this necessarily implying higher disease activity.
Databáze: OpenAIRE
Externí odkaz: